Abstract
Polypharmacy poses a significant risk for adverse reactions. While there are clinical decision support tools to assist clinicians in medication management, pharmacogenetic testing to identify potential drug–gene or drug–drug–gene interactions is not widely implemented in the clinical setting. A PRISMA-compliant scoping review was performed to determine if pharmacogenetic testing for absorption, distribution, metabolism, and excretion (ADME)-related genetic variants is associated with improved clinical outcomes in patients with polypharmacy. Six studies were reviewed. Five reported improved clinical outcomes, reduced side effects, reduction in the number of drugs used, or reduced healthcare utilization. The reviewed studies varied in methodological quality, risk of bias, and outcome measures. Age, diet, disease state, and treatment adherence also influence drug response, and may confound the relationship between genetic polymorphisms and treatment outcomes. Further studies using a randomized control design are needed. We conclude that pharmacogenetic testing represents an opportunity to improve health outcomes in patients exposed to polypharmacy, particularly in patients with psychiatric disorders and the elderly.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
World Health Organization. Medication safety in polypharmacy: technical report. Geneva: World Health Organization; 2019. Available from: https://apps.who.int/iris/handle/10665/325454.
Mair A, Wilson M, Dreischulte T. Addressing the challenge of polypharmacy. Annu Rev Pharm Toxicol. 2020;60:661–81.
Hales CM, Servais J, Martin CB, Kohen D. Prescription drug use among adults aged 40-79 in the United States and Canada. NCHS Data Brief. 2019;347:1–8.
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:230.
Roberts A, Kamdem LK, Weston GS. The pharmacogenetics of drug metabolism. In: Zdanowicz MM, editor. Concepts in pharmacogenomics. 2nd ed. Bethesda, MD: American Society of Health-System Pharmacists; 2017. p. 107–50.
Almazroo OA, Miah MK, Venkataramanan R. Drug metabolism in the liver. Clin Liver Dis. 2017;21:1–20.
Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 2018;19:38–54.
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharm Ther. 2013;138:103–41.
Clinical Pharmacogenetics Implementation Consortium. Retrieved March 2020. https://cpicpgx.org/.
Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharm Ther. 2012;91:321–6.
Bottorff MB, Bright DR, Kisor DF. Commentary: should pharmacogenomic evidence be considered in clinical decision making? Focus on select cardiovascular drugs. Pharmacotherapy. 2017;37:1005–13.
US Food & Drug Administration. Table of pharmacogenomic biomarkers in drug labelling. Retrieved March 2020. https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling.
Baxter. Nexterone (amiodarone HCl) Injection for intravenous use [package insert on the Internet]. Deerfield IL: Baxter; 2011. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022325s002lbl.pdf.
Shah RR, Smith RL. Addressing phenoconversion: the Achilles’ heel of personalized medicine. Br J Clin Pharmacol. 2015;79:222–40.
Klomp SD, Manson ML, Guchelaar HJ, Swen JJ. Phenoconversion of cytochrome P450 metabolism: a systematic review. J Clin Med. 2020;9:2890.
Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169:467–73.
Viswanathan M, Berkman ND, Dryden DM, Hartling L. Assessing risk of bias and confounding in observational studies of interventions or exposures: further development of the RTI item bank [Internet]. Rockville, MD: Agency for Healthcare Research and Quality; 2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK154461/.
Jorgensen AL, Williamson PR. Methodological quality of pharmacogenetic studies: issues of concern. Stat Med. 2008;27:6547–69.
Ross S, Anand SS, Joseph P, Paré G. Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues. JRSM Cardiovasc Dis. 2012;1:2.
Thorn CF, Whirl-Carrillo M, Hachad H, Johnson JA, McDonagh EM, Ratain MJ, et al. Essential characteristics of pharmacogenomics study publications. Clin Pharm Ther. 2019;105:86–9.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
Blasco-Fontecilla H. Clinical utility of pharmacogenetic testing in children and adolescents with severe mental disorders. J Neural Transm. 2019;126:101–7.
Brixner D, Biltaji E, Bress A, Unni S, Ye X, Mamiya T, et al. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ. 2016;19:213–28.
Elliott LS, Henderson JC, Neradilek MB, Moyer NA, Ashcraft KC, Thirumaran RK. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: a prospective pilot randomized controlled trial. PLoS ONE. 2017;12:e0170905.
van der Wouden CH, Bank PCD, Özokcu K, Swen JJ, Guchelaar HJ. Pharmacist-Initiated pre-emptive pharmacogenetic panel testing with clinical decision support in primary care: record of PGx results and real-world impact. Genes. 2019;10:416.
Winner JG, Carhart JM, Altar CA, Allen JD, Dechairo BM. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Disco Med. 2013;16:219–27.
Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Proctor B, Snyder KA, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics. 2013;23:535–48.
Pérez V, Salavert A, Espadaler J, Tuson M, Saiz-Ruiz J, Sáez-Navarro C, et al. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry. 2017;17:250.
Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526:343–50.
Weitzel KW, Cavallari LH, Lesko LJ. Preemptive panel-based pharmacogenetic testing: the time is now. Pharm Res. 2017;34:1551–5.
Cavallari LH, Van Driest SL, Prows CA, Bishop JR, Limdi NA, Pratt VM, et al. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genet Med. 2019;21:2255–63.
Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, et al. The pharmacogenomics research network translational pharmacogenetics program: outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems. Clin Pharm Ther. 2017;102:502–10.
Licito A, Marotta G, Battaglia M, Benincasa G, Mentone L, Grillo MR, et al. Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results. Eur Rev Med Pharm Sci. 2020;24:469–77.
Mugoša S, Djordjević N, Djukanović N, Protić D, Bukumirić Z, Radosavljević I, et al. Factors affecting the development of adverse drug reactions to β-blockers in hospitalized cardiac patient population. Patient Prefer Adherence. 2016;10:1461–9.
Pautas E, Moreau C, Gouin-Thibault I, Golmard JL, Mahé I, Legendre C, et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharm Ther. 2010;87:57–64.
Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther. 2013;17:165–84.
Maciel A, Cullors A, Lukowiak AA, Garces J. Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings. Neuropsychiatr Dis Treat 2018;14:225–30.
Saldivar JS, Taylor D, Sugarman EA, Cullors A, Garces JA, Oades K, et al. Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility. Pharmgenomics Pers Med. 2016;9:1–6.
Sugarman EA, Cullors A, Centeno J, Taylor D. Contribution of pharmacogenetic testing to modeled medication change recommendations in a long-term care population with polypharmacy. Drugs Aging. 2016;33:929–36.
Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017;17:395–402.
van der Wouden CH, van Rhenen MH, Jama WOM, Ingelman-Sundberg M, Lauschke VM, Konta L, et al. Development of the PGx-passport: a panel of actionable germline genetic variants for pre-emptive pharmacogenetic testing. Clin Pharm Ther. 2019;106:866–73.
Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med. 2016;13:e1002160.
Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6–14.
Guttman Y, Nudel A, Kerem Z. Polymorphism in cytochrome P450 3A4 is ethnicity related. Front Genet. 2019;10:224.
Puris E, Pasanen M, Gynther M, Häkkinen MR, Pihlajamäki J, Keränen T, et al. A liquid chromatography-tandem mass spectrometry analysis of nine cytochrome P450 probe drugs and their corresponding metabolites in human serum and urine. Anal Bioanal Chem. 2017;409:251–68.
Alagiakrishnan K, Mah D, Padwal R. Classic challenges and emerging approaches to medication therapy in older adults. Discov Med. 2018;26:137–46.
2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67:674–94.
Lloret-Linares C, Daali Y, Chevret S, Nieto I, Molière F, Courtet P, et al. Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study). BMC Pharm Toxicol. 2017;18:70.
Mariappan TT, Shen H, Marathe P. Endogenous biomarkers to assess drug-drug interactions by drug transporters and enzymes. Curr Drug Metab. 2017;18:757–68.
Vogl S, Lutz RW, Schönfelder G, Lutz WK. CYP2C9 genotype vs. metabolic phenotype for individual drug dosing–a correlation analysis using flurbiprofen as probe drug. PLoS ONE. 2015;10:e0126329.
Acknowledgements
The authors would like to thank Jenessa McElfresh, Health Sciences Librarian (Clemson University), for her assistance during manuscript preparation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Meaddough, E.L., Sarasua, S.M., Fasolino, T.K. et al. The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review. Pharmacogenomics J 21, 409–422 (2021). https://doi.org/10.1038/s41397-021-00224-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41397-021-00224-w
This article is cited by
-
Challenges of pediatric pharmacotherapy: A narrative review of pharmacokinetics, pharmacodynamics, and pharmacogenetics
European Journal of Clinical Pharmacology (2024)
-
Pharmacogenetic profiling via genome sequencing in children with medical complexity
Pediatric Research (2023)